Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;14(3):805-811.
doi: 10.1007/s13555-024-01113-3. Epub 2024 Mar 1.

Botulinum Toxin A and B for Palmoplantar Hyperhidrosis

Trond Eilertsen  1 , Bjørn Øivind Kvammen  2   3 , Øystein Grimstad  2   3
Affiliations

Botulinum Toxin A and B for Palmoplantar Hyperhidrosis

Trond Eilertsen et al. Dermatol Ther (Heidelb). 2024 Mar.

Abstract

Introduction: Hyperhidrosis is characterized by unpredictable, uncontrollable and excessive sweating. It occurs at rest and is not related to temperature. Hyperhidrosis is a common disorder that has a negative impact on quality of life (QoL). The aim of this quality assurance study was to investigate how treatment of palmoplantar hyperhidrosis with botulinum toxin A (BTX-A) and botulinum toxin B (BTX-B) led to improvement of patient reported outcome measures related to QoL.

Methods: A total of 35 patients with palmar and/or plantar hyperhidrosis who had received BTX-A (Dysport®) and BTX-B (NeuroBloc®) for palmar hyperhidrosis and BTX-B for plantar hyperhidrosis were included in this study. In total, palms were injected with a median dose (low to high) of 400 (100-550) units BTX-A and a median dose (low to high) of 200 (200-500) units. BTX-B was used in the thenar and hypothenar areas to avoid muscle weakness. In the soles a total median dose (low to high) of 600 (475-1000) units BTX-B was injected.

Results: At follow-up 2 weeks post-treatment, patients' Dermatology Life Quality Index (DLQI) score improved from 13 to 2 (p < 0.001).

Conclusion: We found that BTX-A and BTX-B treatment for palmar hyperhidrosis and BTX-B treatment for plantar hyperhidrosis led to a substantial improvement of QoL.

Keywords: Botulinum toxin; Dysport®; NeuroBloc®; Palmoplantar hyperhidrosis.

PubMed Disclaimer

Conflict of interest statement

Trond Eilertsen, Bjørn Ø Kvammen, and Øystein Grimstad report no conflicts of interest.

Figures

Fig. 1
Fig. 1
DLQI at baseline and 2 weeks after treatment shown as a box-plot. Box limits represent the range of the central 50% of the data, medians are depicted as a horizontal solid line, whiskers represent maximum and minimum values and outliers are depicted as an open circle. DLQI Dermatology Life Quality Index
Fig. 2
Fig. 2
Results from patients per exclusively treated locations. DLQI Dermatology Life Quality Index
See this image and copyright information in PMC

References

    1. Wade R, Rice S, Llewellyn A, Moloney E, Jones-Diette J, Stoniute J, et al. Interventions for hyperhidrosis in secondary care: a systematic review and value-of-information analysis. Health Technol Assess. 2017;21(80):1–280. doi: 10.3310/hta21800. - DOI - PMC - PubMed
    1. Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308(10):743–749. doi: 10.1007/s00403-016-1697-9. - DOI - PMC - PubMed
    1. Haider A, Solish N. Focal hyperhidrosis: diagnosis and management. Can Med Assoc J. 2005;172(1):69–75. doi: 10.1503/cmaj.1040708. - DOI - PMC - PubMed
    1. Quinton PM. Sweating and its disorders. Annu Rev Med. 1983;34:429–452. doi: 10.1146/annurev.me.34.020183.002241. - DOI - PubMed
    1. Bahar R, Zhou P, Liu Y, Huang Y, Phillips A, Lee TK, et al. The prevalence of anxiety and depression in patients with or without hyperhidrosis (HH) J Am Acad Dermatol. 2016;75(6):1126–1133. doi: 10.1016/j.jaad.2016.07.001. - DOI - PubMed

LinkOut - more resources